NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today that Pluristem’s PLacenta eXpanded (PLX) cells have been demonstrated in vitro to have properties that the Company believes gives these cells the potential to treat Parkinson’s Disease (PD). PLX cells are Pluristem’s placental-derived mesenchymal stem cells (MSCs) that have been expanded in the Company’s proprietary PluriX™ 3-D bioreactor.